Does Semaglutide Increase Risk of a Rare Eye Condition (NAION)? Large-Scale Analysis | Research

The takeaway

Large-scale analysis investigated the potential association between semaglutide/GLP-1 drugs and non-arteritic anterior ischemic optic neuropathy (NAION), addressing safety concerns about a rare eye condition.

NAION risk assessed
Large-scale analysis of the potential association between GLP-1 drugs and a rare optic nerve condition causing sudden vision loss

What the researchers found

Study evaluated the association between semaglutide/GLP-1 RA use and NAION risk using large-scale clinical data, addressing a flagged safety signal for this rare eye condition.

Why it matters

NAION can cause permanent vision loss. With millions taking GLP-1 drugs, even a small increase in NAION risk would affect thousands of people. Clarifying this safety signal is critical.

The numbers in context

Patients aged 12 and older were included. The study used the TriNetX network, which covers millions of U.S. health records. Exact event rates not detailed in available abstract.

How the study worked

Large-scale analysis of clinical data examining the association between GLP-1 receptor agonist use and NAION incidence in patients with T2DM and/or obesity.

Who was studied

U.S. patients aged 12+ prescribed GLP-1 receptor agonists, matched to controls

What this study cannot tell us

NAION is extremely rare, limiting statistical power even in large datasets. Diabetes and obesity themselves are NAION risk factors, confounding the analysis. Observational data cannot prove causation.

How to read the evidence

Moderate evidence: large-scale observational analysis of a rare event, with inherent limitations of confounding and statistical power.

When this study was published

Published in 2025. Addresses an active safety investigation for GLP-1 drugs.

The bigger picture

As GLP-1 drugs become among the most prescribed medications worldwide, post-marketing safety surveillance for rare events becomes increasingly important. NAION is very rare (~2-10 per 100,000), making large datasets essential for detecting any meaningful risk change.

Questions still open

Is the NAION signal specific to semaglutide or shared across all GLP-1 drugs?
Does rapid weight loss itself contribute to NAION risk regardless of drug used?
Should patients with pre-existing optic nerve conditions avoid GLP-1 drugs?

Common questions

Can semaglutide cause vision problems?

NAION (sudden vision loss from optic nerve blood flow blockage) has been flagged as a potential concern. This large-scale analysis evaluated the evidence. NAION is very rare, and diabetes itself is a risk factor. Any sudden vision change should be reported to your doctor.

Should I stop my GLP-1 drug because of NAION concerns?

Do not stop medication without consulting your doctor. NAION is extremely rare, and the benefits of GLP-1 drugs for diabetes and obesity management are well-established. Discuss any concerns with your prescriber.

Read the original research

The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy.

American journal of ophthalmology, 274, 24-31

View on PubMed ↗Publisher’s paper ↗

Citation

Abbass, Nadia J; Nahlawi, Raya; Shaia, Jacqueline K; Allan, Kevin C; Kaelber, David C; Talcott, Katherine E; Singh, Rishi P. (2025). The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy.. American journal of ophthalmology, 274, 24-31. https://doi.org/10.1016/j.ajo.2025.02.025